Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors

Trial Profile

A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2019

At a glance

  • Drugs Adavosertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2019 Updated results from one daily dosing of adavosertib (arm B; n=34) presented at the 110th Annual Meeting of the American Association for Cancer Research.
    • 02 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Nov 2018 Planned End Date changed from 20 May 2019 to 27 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top